Fine Mark National Bank & Trust Nektar Therapeutics Transaction History

Fine Mark National Bank & Trust

  • $2.84 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2018

Nov 02, 2018
SELL
$46.46 - $68.49 $418,140 - $616,410
-9,000 Closed
0 $0
Q2 2018

Aug 03, 2018
SELL
$46.25 - $104.45 $3,700 - $8,356
-80 Reduced 0.88%
9,000 $439,000
Q1 2018

Apr 26, 2018
BUY
$57.4 - $108.44 $521,192 - $984,635
9,080 New
9,080 $965,000

Others Institutions Holding NKTR

# of Institutions
146
Shares Held
139M
Call Options Held
32.6K
Put Options Held
14.1K
View Full List

About NEKTAR THERAPEUTICS

NKTR Quotes by TradingView
  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $212M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Fine Mark National Bank & Trust Portfolio

Follow Fine Mark National Bank & Trust and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fine Mark National Bank & Trust, based on Form 13F filings with the SEC.

News

Stay updated on Fine Mark National Bank & Trust with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email